Insight

Oct 16, 2024, 15:08

The utility of ctDNA clearance for personalizing consolidation immunotherapy after CRT for stage III NSCLC

Drew Moghanaki shared a post on X:

“A new publication from Max Diehn‘s group re-demonstrates the utility of ctDNA clearance for personalizing consolidation immunotherapy after CRT for stage III NSCLC.

Analysis of Circulating Tumor DNA Predicts Outcomes of Short-Course Consolidation Immunotherapy in Unresectable Stage III NSCLC

Authors: Soyeong Jun, Nikhil A. Shukla, Greg Durm, Angela B. Hui, Sha Cao, Apar Kishor Ganti, Salma K. Jabbour, Christian Kunder, Ash A. Alizadeh, Nasser H. Hanna, Maximilian Diehn.“

Dr. Drew Moghanaki, a Professor and Chief of Thoracic Oncology at the Department of Radiation Oncology, UCLA. He holds the Stanley Iezman and Nancy Stark Endowed Chair in Thoracic Radiation Oncology Research at the same university. He specializes in treating lung cancer and other thoracic malignancies, focusing on advanced radiation therapy techniques like stereotactic body radiation therapy (SBRT), magnetic resonance-guided radiation therapy (MRgRT), and intensity-modulated radiation therapy (IMRT).

Angela B. Hui Apar Kishor Ganti Ash A. Alizadeh cancer Christian Kunder CRT ctDNA Drew Moghanaki Greg Durm Maximilian Diehn Nasser H. Hanna Nikhil A. Shukla OncoDaily Oncology Salma K. Jabbour Sha Cao Soyeong Jun stage III NSCLC

Top 100 Xfluencers in Lung Cancer: Key Opinion Leaders to Follow on X (Twitter) in 2024

100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2024: Part 10

OncoThon 2024 Raises $1.3 Million for Pediatric Cancer Research

Richard Sullivan: Do we need a 'new' Geneva Convention and protocols?

Remembering Virgil Abloh: Louis Vuitton’s Creative Director Honored at 41 After His Brave Battle with Cardiac Angiosarcoma

Special Coverage